

Global HCC (Hepatocellular Carcinoma) Biomarker Market Growth (Status and Outlook) 2026-2032

<https://marketpublishers.com/r/G07CD6A4AD9BEN.html>

Date: August 2026

Pages: 106

Price: US\$ 3,660.00 (Single User License)

ID: G07CD6A4AD9BEN

Abstracts

The global HCC (Hepatocellular Carcinoma) Biomarker market size is predicted to grow from US\$ 921 million in 2025 to US\$ 1414 million in 2032; it is expected to grow at a CAGR of 6.4% from 2026 to 2032.

Hepatocellular carcinoma (HCC) is the seventh most common cancer diagnosis worldwide with high associated mortality. HCC is a unique malignancy, as it typically arises in the setting of chronic liver disease in particular cirrhosis, with competing risks of liver failure, contributing to its low 5-year survival rates of 18%-20%. More than half of worldwide HCC-related deaths occur in Asia, due to endemic hepatitis B (HBV) infection. HCC incidence is rising in many Western countries due to the rising prevalence of nonalcoholic fatty liver disease, alcohol-related liver disease, and hepatitis C (HCV)-related complications despite the availability of direct acting antiviral therapies. The search for biomarkers in hepatocellular carcinoma continues despite recent approvals for immune checkpoint inhibitor combinations, tyrosine kinase inhibitors [TKIs], and antiangiogenic agents. Biomarkers can be either predictive or prognostic and the only biomarker that has been used clinically is the prognostic biomarker α -fetoprotein (AFP).

United States market for HCC (Hepatocellular Carcinoma) Biomarker is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

China market for HCC (Hepatocellular Carcinoma) Biomarker is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

Europe market for HCC (Hepatocellular Carcinoma) Biomarker is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

Global key HCC (Hepatocellular Carcinoma) Biomarker players cover FUJIFILM, Eli Lilly and Company, Fujirebio, Roche Diagnostics, Fapon Biotech, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.

LPI (LP Information)' newest research report, the "HCC (Hepatocellular Carcinoma) Biomarker Industry Forecast" looks at past sales and reviews total world HCC (Hepatocellular Carcinoma) Biomarker sales in 2025, providing a comprehensive analysis by region and market sector of projected HCC (Hepatocellular Carcinoma) Biomarker sales for 2026 through 2032. With HCC (Hepatocellular Carcinoma) Biomarker sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world HCC (Hepatocellular Carcinoma) Biomarker industry.

This Insight Report provides a comprehensive analysis of the global HCC (Hepatocellular Carcinoma) Biomarker landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on HCC (Hepatocellular Carcinoma) Biomarker portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global HCC (Hepatocellular Carcinoma) Biomarker market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for HCC (Hepatocellular Carcinoma) Biomarker and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global HCC (Hepatocellular Carcinoma) Biomarker.

This report presents a comprehensive overview, market shares, and growth opportunities of HCC (Hepatocellular Carcinoma) Biomarker market by product type, application, key players and key regions and countries.

Segmentation by Type:

Alpha-fetoprotein (AFP)

Des-?-carboxy Prothrombin (DCP)

Others

Segmentation by Application:

Hospitals

Clinics

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

FUJIFILM

Eli Lilly and Company

Fujirebio

Roche Diagnostics

Fapon Biotech

Labcorp

Thermo Fisher Scientific

Abcam

Bio-Techne

MyBiosource

RayBiotech

CUSABIO

Elabscience Biotechnology

Abbexa

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global HCC (Hepatocellular Carcinoma) Biomarker Market Size (2021-2032)
 - 2.1.2 HCC (Hepatocellular Carcinoma) Biomarker Market Size CAGR by Region (2021 VS 2025 VS 2032)
 - 2.1.3 World Current & Future Analysis for HCC (Hepatocellular Carcinoma) Biomarker by Country/Region (2021, 2025 & 2032)
- 2.2 HCC (Hepatocellular Carcinoma) Biomarker Segment by Type
 - 2.2.1 Alpha-fetoprotein (AFP)
 - 2.2.2 Des-?-carboxy Prothrombin (DCP)
 - 2.2.3 Others
 - 2.2.4 HCC (Hepatocellular Carcinoma) Biomarker Market Size by Type
 - 2.2.4.1 HCC (Hepatocellular Carcinoma) Biomarker Market Size CAGR by Type (2021 VS 2025 VS 2032)
 - 2.2.4.2 Global HCC (Hepatocellular Carcinoma) Biomarker Market Size Market Share by Type (2021-2026)
- 2.3 HCC (Hepatocellular Carcinoma) Biomarker Segment by Application
 - 2.3.1 Hospitals
 - 2.3.2 Clinics
 - 2.3.3 Others
 - 2.3.4 HCC (Hepatocellular Carcinoma) Biomarker Market Size by Application
 - 2.3.4.1 HCC (Hepatocellular Carcinoma) Biomarker Market Size CAGR by Application (2021 VS 2025 VS 2032)
 - 2.3.4.2 Global HCC (Hepatocellular Carcinoma) Biomarker Market Size Market Share by Application (2021-2026)

3 HCC (HEPATOCELLULAR CARCINOMA) BIOMARKER MARKET SIZE BY PLAYER

3.1 HCC (Hepatocellular Carcinoma) Biomarker Market Size Market Share by Player

3.1.1 Global HCC (Hepatocellular Carcinoma) Biomarker Revenue by Player (2021-2026)

3.1.2 Global HCC (Hepatocellular Carcinoma) Biomarker Revenue Market Share by Player (2021-2026)

3.2 Global HCC (Hepatocellular Carcinoma) Biomarker Key Players Head office and Products Offered

3.3 Market Concentration Rate Analysis

3.3.1 Competition Landscape Analysis

3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

3.4 New Products and Potential Entrants

3.5 Mergers & Acquisitions, Expansion

4 HCC (HEPATOCELLULAR CARCINOMA) BIOMARKER BY REGION

4.1 HCC (Hepatocellular Carcinoma) Biomarker Market Size by Region (2021-2026)

4.2 Global HCC (Hepatocellular Carcinoma) Biomarker Annual Revenue by Country/Region (2021-2026)

4.3 Americas HCC (Hepatocellular Carcinoma) Biomarker Market Size Growth (2021-2026)

4.4 APAC HCC (Hepatocellular Carcinoma) Biomarker Market Size Growth (2021-2026)

4.5 Europe HCC (Hepatocellular Carcinoma) Biomarker Market Size Growth (2021-2026)

4.6 Middle East & Africa HCC (Hepatocellular Carcinoma) Biomarker Market Size Growth (2021-2026)

5 AMERICAS

5.1 Americas HCC (Hepatocellular Carcinoma) Biomarker Market Size by Country (2021-2026)

5.2 Americas HCC (Hepatocellular Carcinoma) Biomarker Market Size by Type (2021-2026)

5.3 Americas HCC (Hepatocellular Carcinoma) Biomarker Market Size by Application (2021-2026)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC HCC (Hepatocellular Carcinoma) Biomarker Market Size by Region
(2021-2026)

6.2 APAC HCC (Hepatocellular Carcinoma) Biomarker Market Size by Type
(2021-2026)

6.3 APAC HCC (Hepatocellular Carcinoma) Biomarker Market Size by Application
(2021-2026)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

7 EUROPE

7.1 Europe HCC (Hepatocellular Carcinoma) Biomarker Market Size by Country
(2021-2026)

7.2 Europe HCC (Hepatocellular Carcinoma) Biomarker Market Size by Type
(2021-2026)

7.3 Europe HCC (Hepatocellular Carcinoma) Biomarker Market Size by Application
(2021-2026)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa HCC (Hepatocellular Carcinoma) Biomarker by Region
(2021-2026)

8.2 Middle East & Africa HCC (Hepatocellular Carcinoma) Biomarker Market Size by
Type (2021-2026)

8.3 Middle East & Africa HCC (Hepatocellular Carcinoma) Biomarker Market Size by Application (2021-2026)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 GLOBAL HCC (HEPATOCELLULAR CARCINOMA) BIOMARKER MARKET FORECAST

10.1 Global HCC (Hepatocellular Carcinoma) Biomarker Forecast by Region (2027-2032)

10.1.1 Global HCC (Hepatocellular Carcinoma) Biomarker Forecast by Region (2027-2032)

10.1.2 Americas HCC (Hepatocellular Carcinoma) Biomarker Forecast

10.1.3 APAC HCC (Hepatocellular Carcinoma) Biomarker Forecast

10.1.4 Europe HCC (Hepatocellular Carcinoma) Biomarker Forecast

10.1.5 Middle East & Africa HCC (Hepatocellular Carcinoma) Biomarker Forecast

10.2 Americas HCC (Hepatocellular Carcinoma) Biomarker Forecast by Country (2027-2032)

10.2.1 United States Market HCC (Hepatocellular Carcinoma) Biomarker Forecast

10.2.2 Canada Market HCC (Hepatocellular Carcinoma) Biomarker Forecast

10.2.3 Mexico Market HCC (Hepatocellular Carcinoma) Biomarker Forecast

10.2.4 Brazil Market HCC (Hepatocellular Carcinoma) Biomarker Forecast

10.3 APAC HCC (Hepatocellular Carcinoma) Biomarker Forecast by Region (2027-2032)

10.3.1 China HCC (Hepatocellular Carcinoma) Biomarker Market Forecast

10.3.2 Japan Market HCC (Hepatocellular Carcinoma) Biomarker Forecast

10.3.3 Korea Market HCC (Hepatocellular Carcinoma) Biomarker Forecast

10.3.4 Southeast Asia Market HCC (Hepatocellular Carcinoma) Biomarker Forecast

10.3.5 India Market HCC (Hepatocellular Carcinoma) Biomarker Forecast

10.3.6 Australia Market HCC (Hepatocellular Carcinoma) Biomarker Forecast

10.4 Europe HCC (Hepatocellular Carcinoma) Biomarker Forecast by Country (2027-2032)

10.4.1 Germany Market HCC (Hepatocellular Carcinoma) Biomarker Forecast

10.4.2 France Market HCC (Hepatocellular Carcinoma) Biomarker Forecast

10.4.3 UK Market HCC (Hepatocellular Carcinoma) Biomarker Forecast

10.4.4 Italy Market HCC (Hepatocellular Carcinoma) Biomarker Forecast

10.4.5 Russia Market HCC (Hepatocellular Carcinoma) Biomarker Forecast

10.5 Middle East & Africa HCC (Hepatocellular Carcinoma) Biomarker Forecast by Region (2027-2032)

10.5.1 Egypt Market HCC (Hepatocellular Carcinoma) Biomarker Forecast

10.5.2 South Africa Market HCC (Hepatocellular Carcinoma) Biomarker Forecast

10.5.3 Israel Market HCC (Hepatocellular Carcinoma) Biomarker Forecast

10.5.4 Turkey Market HCC (Hepatocellular Carcinoma) Biomarker Forecast

10.6 Global HCC (Hepatocellular Carcinoma) Biomarker Forecast by Type (2027-2032)

10.7 Global HCC (Hepatocellular Carcinoma) Biomarker Forecast by Application (2027-2032)

10.7.1 GCC Countries Market HCC (Hepatocellular Carcinoma) Biomarker Forecast

11 KEY PLAYERS ANALYSIS

11.1 FUJIFILM

11.1.1 FUJIFILM Company Information

11.1.2 FUJIFILM HCC (Hepatocellular Carcinoma) Biomarker Product Offered

11.1.3 FUJIFILM HCC (Hepatocellular Carcinoma) Biomarker Revenue, Gross Margin and Market Share (2021-2026)

11.1.4 FUJIFILM Main Business Overview

11.1.5 FUJIFILM Latest Developments

11.2 Eli Lilly and Company

11.2.1 Eli Lilly and Company Company Information

11.2.2 Eli Lilly and Company HCC (Hepatocellular Carcinoma) Biomarker Product Offered

11.2.3 Eli Lilly and Company HCC (Hepatocellular Carcinoma) Biomarker Revenue, Gross Margin and Market Share (2021-2026)

11.2.4 Eli Lilly and Company Main Business Overview

11.2.5 Eli Lilly and Company Latest Developments

11.3 Fujirebio

11.3.1 Fujirebio Company Information

11.3.2 Fujirebio HCC (Hepatocellular Carcinoma) Biomarker Product Offered

11.3.3 Fujirebio HCC (Hepatocellular Carcinoma) Biomarker Revenue, Gross Margin

and Market Share (2021-2026)

11.3.4 Fujirebio Main Business Overview

11.3.5 Fujirebio Latest Developments

11.4 Roche Diagnostics

11.4.1 Roche Diagnostics Company Information

11.4.2 Roche Diagnostics HCC (Hepatocellular Carcinoma) Biomarker Product Offered

11.4.3 Roche Diagnostics HCC (Hepatocellular Carcinoma) Biomarker Revenue, Gross Margin and Market Share (2021-2026)

11.4.4 Roche Diagnostics Main Business Overview

11.4.5 Roche Diagnostics Latest Developments

11.5 Fapon Biotech

11.5.1 Fapon Biotech Company Information

11.5.2 Fapon Biotech HCC (Hepatocellular Carcinoma) Biomarker Product Offered

11.5.3 Fapon Biotech HCC (Hepatocellular Carcinoma) Biomarker Revenue, Gross Margin and Market Share (2021-2026)

11.5.4 Fapon Biotech Main Business Overview

11.5.5 Fapon Biotech Latest Developments

11.6 Labcorp

11.6.1 Labcorp Company Information

11.6.2 Labcorp HCC (Hepatocellular Carcinoma) Biomarker Product Offered

11.6.3 Labcorp HCC (Hepatocellular Carcinoma) Biomarker Revenue, Gross Margin and Market Share (2021-2026)

11.6.4 Labcorp Main Business Overview

11.6.5 Labcorp Latest Developments

11.7 Thermo Fisher Scientific

11.7.1 Thermo Fisher Scientific Company Information

11.7.2 Thermo Fisher Scientific HCC (Hepatocellular Carcinoma) Biomarker Product Offered

11.7.3 Thermo Fisher Scientific HCC (Hepatocellular Carcinoma) Biomarker Revenue, Gross Margin and Market Share (2021-2026)

11.7.4 Thermo Fisher Scientific Main Business Overview

11.7.5 Thermo Fisher Scientific Latest Developments

11.8 Abcam

11.8.1 Abcam Company Information

11.8.2 Abcam HCC (Hepatocellular Carcinoma) Biomarker Product Offered

11.8.3 Abcam HCC (Hepatocellular Carcinoma) Biomarker Revenue, Gross Margin and Market Share (2021-2026)

11.8.4 Abcam Main Business Overview

- 11.8.5 Abcam Latest Developments
- 11.9 Bio-Techne
 - 11.9.1 Bio-Techne Company Information
 - 11.9.2 Bio-Techne HCC (Hepatocellular Carcinoma) Biomarker Product Offered
 - 11.9.3 Bio-Techne HCC (Hepatocellular Carcinoma) Biomarker Revenue, Gross Margin and Market Share (2021-2026)
 - 11.9.4 Bio-Techne Main Business Overview
 - 11.9.5 Bio-Techne Latest Developments
- 11.10 MyBiosource
 - 11.10.1 MyBiosource Company Information
 - 11.10.2 MyBiosource HCC (Hepatocellular Carcinoma) Biomarker Product Offered
 - 11.10.3 MyBiosource HCC (Hepatocellular Carcinoma) Biomarker Revenue, Gross Margin and Market Share (2021-2026)
 - 11.10.4 MyBiosource Main Business Overview
 - 11.10.5 MyBiosource Latest Developments
- 11.11 RayBiotech
 - 11.11.1 RayBiotech Company Information
 - 11.11.2 RayBiotech HCC (Hepatocellular Carcinoma) Biomarker Product Offered
 - 11.11.3 RayBiotech HCC (Hepatocellular Carcinoma) Biomarker Revenue, Gross Margin and Market Share (2021-2026)
 - 11.11.4 RayBiotech Main Business Overview
 - 11.11.5 RayBiotech Latest Developments
- 11.12 CUSABIO
 - 11.12.1 CUSABIO Company Information
 - 11.12.2 CUSABIO HCC (Hepatocellular Carcinoma) Biomarker Product Offered
 - 11.12.3 CUSABIO HCC (Hepatocellular Carcinoma) Biomarker Revenue, Gross Margin and Market Share (2021-2026)
 - 11.12.4 CUSABIO Main Business Overview
 - 11.12.5 CUSABIO Latest Developments
- 11.13 Elabscience Biotechnology
 - 11.13.1 Elabscience Biotechnology Company Information
 - 11.13.2 Elabscience Biotechnology HCC (Hepatocellular Carcinoma) Biomarker Product Offered
 - 11.13.3 Elabscience Biotechnology HCC (Hepatocellular Carcinoma) Biomarker Revenue, Gross Margin and Market Share (2021-2026)
 - 11.13.4 Elabscience Biotechnology Main Business Overview
 - 11.13.5 Elabscience Biotechnology Latest Developments
- 11.14 Abbexa
 - 11.14.1 Abbexa Company Information

11.14.2 Abbexa HCC (Hepatocellular Carcinoma) Biomarker Product Offered

11.14.3 Abbexa HCC (Hepatocellular Carcinoma) Biomarker Revenue, Gross Margin and Market Share (2021-2026)

11.14.4 Abbexa Main Business Overview

11.14.5 Abbexa Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. HCC (Hepatocellular Carcinoma) Biomarker Market Size CAGR by Region (2021 VS 2025 VS 2032) & (\$ millions)

Table 2. HCC (Hepatocellular Carcinoma) Biomarker Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)

Table 3. Major Players of Alpha-fetoprotein (AFP)

Table 4. Major Players of Des-?-carboxy Prothrombin (DCP)

Table 5. Major Players of Others

Table 6. HCC (Hepatocellular Carcinoma) Biomarker Market Size CAGR by Type (2021 VS 2025 VS 2032) & (\$ millions)

Table 7. Global HCC (Hepatocellular Carcinoma) Biomarker Market Size by Type (2021-2026) & (\$ millions)

Table 8. Global HCC (Hepatocellular Carcinoma) Biomarker Market Size Market Share by Type (2021-2026)

Table 9. HCC (Hepatocellular Carcinoma) Biomarker Market Size CAGR by Application (2021 VS 2025 VS 2032) & (\$ millions)

Table 10. Global HCC (Hepatocellular Carcinoma) Biomarker Market Size by Application (2021-2026) & (\$ millions)

Table 11. Global HCC (Hepatocellular Carcinoma) Biomarker Market Size Market Share by Application (2021-2026)

Table 12. Global HCC (Hepatocellular Carcinoma) Biomarker Revenue by Player (2021-2026) & (\$ millions)

Table 13. Global HCC (Hepatocellular Carcinoma) Biomarker Revenue Market Share by Player (2021-2026)

Table 14. HCC (Hepatocellular Carcinoma) Biomarker Key Players Head office and Products Offered

Table 15. HCC (Hepatocellular Carcinoma) Biomarker Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

Table 16. New Products and Potential Entrants

Table 17. Mergers & Acquisitions, Expansion

Table 18. Global HCC (Hepatocellular Carcinoma) Biomarker Market Size by Region (2021-2026) & (\$ millions)

Table 19. Global HCC (Hepatocellular Carcinoma) Biomarker Market Size Market Share by Region (2021-2026)

Table 20. Global HCC (Hepatocellular Carcinoma) Biomarker Revenue by Country/Region (2021-2026) & (\$ millions)

Table 21. Global HCC (Hepatocellular Carcinoma) Biomarker Revenue Market Share by Country/Region (2021-2026)

Table 22. Americas HCC (Hepatocellular Carcinoma) Biomarker Market Size by Country (2021-2026) & (\$ millions)

Table 23. Americas HCC (Hepatocellular Carcinoma) Biomarker Market Size Market Share by Country (2021-2026)

Table 24. Americas HCC (Hepatocellular Carcinoma) Biomarker Market Size by Type (2021-2026) & (\$ millions)

Table 25. Americas HCC (Hepatocellular Carcinoma) Biomarker Market Size Market Share by Type (2021-2026)

Table 26. Americas HCC (Hepatocellular Carcinoma) Biomarker Market Size by Application (2021-2026) & (\$ millions)

Table 27. Americas HCC (Hepatocellular Carcinoma) Biomarker Market Size Market Share by Application (2021-2026)

Table 28. APAC HCC (Hepatocellular Carcinoma) Biomarker Market Size by Region (2021-2026) & (\$ millions)

Table 29. APAC HCC (Hepatocellular Carcinoma) Biomarker Market Size Market Share by Region (2021-2026)

Table 30. APAC HCC (Hepatocellular Carcinoma) Biomarker Market Size by Type (2021-2026) & (\$ millions)

Table 31. APAC HCC (Hepatocellular Carcinoma) Biomarker Market Size by Application (2021-2026) & (\$ millions)

Table 32. Europe HCC (Hepatocellular Carcinoma) Biomarker Market Size by Country (2021-2026) & (\$ millions)

Table 33. Europe HCC (Hepatocellular Carcinoma) Biomarker Market Size Market Share by Country (2021-2026)

Table 34. Europe HCC (Hepatocellular Carcinoma) Biomarker Market Size by Type (2021-2026) & (\$ millions)

Table 35. Europe HCC (Hepatocellular Carcinoma) Biomarker Market Size by Application (2021-2026) & (\$ millions)

Table 36. Middle East & Africa HCC (Hepatocellular Carcinoma) Biomarker Market Size by Region (2021-2026) & (\$ millions)

Table 37. Middle East & Africa HCC (Hepatocellular Carcinoma) Biomarker Market Size by Type (2021-2026) & (\$ millions)

Table 38. Middle East & Africa HCC (Hepatocellular Carcinoma) Biomarker Market Size by Application (2021-2026) & (\$ millions)

Table 39. Key Market Drivers & Growth Opportunities of HCC (Hepatocellular Carcinoma) Biomarker

Table 40. Key Market Challenges & Risks of HCC (Hepatocellular Carcinoma)

Biomarker

Table 41. Key Industry Trends of HCC (Hepatocellular Carcinoma) Biomarker

Table 42. Global HCC (Hepatocellular Carcinoma) Biomarker Market Size Forecast by Region (2027-2032) & (\$ millions)

Table 43. Global HCC (Hepatocellular Carcinoma) Biomarker Market Size Market Share Forecast by Region (2027-2032)

Table 44. Global HCC (Hepatocellular Carcinoma) Biomarker Market Size Forecast by Type (2027-2032) & (\$ millions)

Table 45. Global HCC (Hepatocellular Carcinoma) Biomarker Market Size Forecast by Application (2027-2032) & (\$ millions)

Table 46. FUJIFILM Details, Company Type, HCC (Hepatocellular Carcinoma) Biomarker Area Served and Its Competitors

Table 47. FUJIFILM HCC (Hepatocellular Carcinoma) Biomarker Product Offered

Table 48. FUJIFILM HCC (Hepatocellular Carcinoma) Biomarker Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 49. FUJIFILM Main Business

Table 50. FUJIFILM Latest Developments

Table 51. Eli Lilly and Company Details, Company Type, HCC (Hepatocellular Carcinoma) Biomarker Area Served and Its Competitors

Table 52. Eli Lilly and Company HCC (Hepatocellular Carcinoma) Biomarker Product Offered

Table 53. Eli Lilly and Company HCC (Hepatocellular Carcinoma) Biomarker Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 54. Eli Lilly and Company Main Business

Table 55. Eli Lilly and Company Latest Developments

Table 56. Fujirebio Details, Company Type, HCC (Hepatocellular Carcinoma) Biomarker Area Served and Its Competitors

Table 57. Fujirebio HCC (Hepatocellular Carcinoma) Biomarker Product Offered

Table 58. Fujirebio HCC (Hepatocellular Carcinoma) Biomarker Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 59. Fujirebio Main Business

Table 60. Fujirebio Latest Developments

Table 61. Roche Diagnostics Details, Company Type, HCC (Hepatocellular Carcinoma) Biomarker Area Served and Its Competitors

Table 62. Roche Diagnostics HCC (Hepatocellular Carcinoma) Biomarker Product Offered

Table 63. Roche Diagnostics HCC (Hepatocellular Carcinoma) Biomarker Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 64. Roche Diagnostics Main Business

Table 65. Roche Diagnostics Latest Developments

Table 66. Fapon Biotech Details, Company Type, HCC (Hepatocellular Carcinoma) Biomarker Area Served and Its Competitors

Table 67. Fapon Biotech HCC (Hepatocellular Carcinoma) Biomarker Product Offered

Table 68. Fapon Biotech HCC (Hepatocellular Carcinoma) Biomarker Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 69. Fapon Biotech Main Business

Table 70. Fapon Biotech Latest Developments

Table 71. Labcorp Details, Company Type, HCC (Hepatocellular Carcinoma) Biomarker Area Served and Its Competitors

Table 72. Labcorp HCC (Hepatocellular Carcinoma) Biomarker Product Offered

Table 73. Labcorp HCC (Hepatocellular Carcinoma) Biomarker Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 74. Labcorp Main Business

Table 75. Labcorp Latest Developments

Table 76. Thermo Fisher Scientific Details, Company Type, HCC (Hepatocellular Carcinoma) Biomarker Area Served and Its Competitors

Table 77. Thermo Fisher Scientific HCC (Hepatocellular Carcinoma) Biomarker Product Offered

Table 78. Thermo Fisher Scientific HCC (Hepatocellular Carcinoma) Biomarker Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 79. Thermo Fisher Scientific Main Business

Table 80. Thermo Fisher Scientific Latest Developments

Table 81. Abcam Details, Company Type, HCC (Hepatocellular Carcinoma) Biomarker Area Served and Its Competitors

Table 82. Abcam HCC (Hepatocellular Carcinoma) Biomarker Product Offered

Table 83. Abcam HCC (Hepatocellular Carcinoma) Biomarker Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 84. Abcam Main Business

Table 85. Abcam Latest Developments

Table 86. Bio-Techne Details, Company Type, HCC (Hepatocellular Carcinoma) Biomarker Area Served and Its Competitors

Table 87. Bio-Techne HCC (Hepatocellular Carcinoma) Biomarker Product Offered

Table 88. Bio-Techne HCC (Hepatocellular Carcinoma) Biomarker Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 89. Bio-Techne Main Business

Table 90. Bio-Techne Latest Developments

Table 91. MyBiosource Details, Company Type, HCC (Hepatocellular Carcinoma) Biomarker Area Served and Its Competitors

Table 92. MyBiosource HCC (Hepatocellular Carcinoma) Biomarker Product Offered

Table 93. MyBiosource HCC (Hepatocellular Carcinoma) Biomarker Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 94. MyBiosource Main Business

Table 95. MyBiosource Latest Developments

Table 96. RayBiotech Details, Company Type, HCC (Hepatocellular Carcinoma) Biomarker Area Served and Its Competitors

Table 97. RayBiotech HCC (Hepatocellular Carcinoma) Biomarker Product Offered

Table 98. RayBiotech HCC (Hepatocellular Carcinoma) Biomarker Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 99. RayBiotech Main Business

Table 100. RayBiotech Latest Developments

Table 101. CUSABIO Details, Company Type, HCC (Hepatocellular Carcinoma) Biomarker Area Served and Its Competitors

Table 102. CUSABIO HCC (Hepatocellular Carcinoma) Biomarker Product Offered

Table 103. CUSABIO HCC (Hepatocellular Carcinoma) Biomarker Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 104. CUSABIO Main Business

Table 105. CUSABIO Latest Developments

Table 106. Elabscience Biotechnology Details, Company Type, HCC (Hepatocellular Carcinoma) Biomarker Area Served and Its Competitors

Table 107. Elabscience Biotechnology HCC (Hepatocellular Carcinoma) Biomarker Product Offered

Table 108. Elabscience Biotechnology HCC (Hepatocellular Carcinoma) Biomarker Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 109. Elabscience Biotechnology Main Business

Table 110. Elabscience Biotechnology Latest Developments

Table 111. Abbexa Details, Company Type, HCC (Hepatocellular Carcinoma) Biomarker Area Served and Its Competitors

Table 112. Abbexa HCC (Hepatocellular Carcinoma) Biomarker Product Offered

Table 113. Abbexa HCC (Hepatocellular Carcinoma) Biomarker Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 114. Abbexa Main Business

Table 115. Abbexa Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. HCC (Hepatocellular Carcinoma) Biomarker Report Years Considered

Figure 2. Research Objectives

Figure 3. Research Methodology

Figure 4. Research Process and Data Source

Figure 5. Global HCC (Hepatocellular Carcinoma) Biomarker Market Size Growth Rate (2021-2032) (\$ millions)

Figure 6. HCC (Hepatocellular Carcinoma) Biomarker Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Figure 7. HCC (Hepatocellular Carcinoma) Biomarker Sales Market Share by Country/Region (2025)

Figure 8. HCC (Hepatocellular Carcinoma) Biomarker Sales Market Share by Country/Region (2021, 2025 & 2032)

Figure 9. Global HCC (Hepatocellular Carcinoma) Biomarker Market Size Market Share by Type in 2025

Figure 10. HCC (Hepatocellular Carcinoma) Biomarker in Hospitals

Figure 11. Global HCC (Hepatocellular Carcinoma) Biomarker Market: Hospitals (2021-2026) & (\$ millions)

Figure 12. HCC (Hepatocellular Carcinoma) Biomarker in Clinics

Figure 13. Global HCC (Hepatocellular Carcinoma) Biomarker Market: Clinics (2021-2026) & (\$ millions)

Figure 14. HCC (Hepatocellular Carcinoma) Biomarker in Others

Figure 15. Global HCC (Hepatocellular Carcinoma) Biomarker Market: Others (2021-2026) & (\$ millions)

Figure 16. Global HCC (Hepatocellular Carcinoma) Biomarker Market Size Market Share by Application in 2025

Figure 17. Global HCC (Hepatocellular Carcinoma) Biomarker Revenue Market Share by Player in 2025

Figure 18. Global HCC (Hepatocellular Carcinoma) Biomarker Market Size Market Share by Region (2021-2026)

Figure 19. Americas HCC (Hepatocellular Carcinoma) Biomarker Market Size 2021-2026 (\$ millions)

Figure 20. APAC HCC (Hepatocellular Carcinoma) Biomarker Market Size 2021-2026 (\$ millions)

Figure 21. Europe HCC (Hepatocellular Carcinoma) Biomarker Market Size 2021-2026 (\$ millions)

Figure 22. Middle East & Africa HCC (Hepatocellular Carcinoma) Biomarker Market Size 2021-2026 (\$ millions)

Figure 23. Americas HCC (Hepatocellular Carcinoma) Biomarker Value Market Share by Country in 2025

Figure 24. United States HCC (Hepatocellular Carcinoma) Biomarker Market Size Growth 2021-2026 (\$ millions)

Figure 25. Canada HCC (Hepatocellular Carcinoma) Biomarker Market Size Growth 2021-2026 (\$ millions)

Figure 26. Mexico HCC (Hepatocellular Carcinoma) Biomarker Market Size Growth 2021-2026 (\$ millions)

Figure 27. Brazil HCC (Hepatocellular Carcinoma) Biomarker Market Size Growth 2021-2026 (\$ millions)

Figure 28. APAC HCC (Hepatocellular Carcinoma) Biomarker Market Size Market Share by Region in 2025

Figure 29. APAC HCC (Hepatocellular Carcinoma) Biomarker Market Size Market Share by Type (2021-2026)

Figure 30. APAC HCC (Hepatocellular Carcinoma) Biomarker Market Size Market Share by Application (2021-2026)

Figure 31. China HCC (Hepatocellular Carcinoma) Biomarker Market Size Growth 2021-2026 (\$ millions)

Figure 32. Japan HCC (Hepatocellular Carcinoma) Biomarker Market Size Growth 2021-2026 (\$ millions)

Figure 33. South Korea HCC (Hepatocellular Carcinoma) Biomarker Market Size Growth 2021-2026 (\$ millions)

Figure 34. Southeast Asia HCC (Hepatocellular Carcinoma) Biomarker Market Size Growth 2021-2026 (\$ millions)

Figure 35. India HCC (Hepatocellular Carcinoma) Biomarker Market Size Growth 2021-2026 (\$ millions)

Figure 36. Australia HCC (Hepatocellular Carcinoma) Biomarker Market Size Growth 2021-2026 (\$ millions)

Figure 37. Europe HCC (Hepatocellular Carcinoma) Biomarker Market Size Market Share by Country in 2025

Figure 38. Europe HCC (Hepatocellular Carcinoma) Biomarker Market Size Market Share by Type (2021-2026)

Figure 39. Europe HCC (Hepatocellular Carcinoma) Biomarker Market Size Market Share by Application (2021-2026)

Figure 40. Germany HCC (Hepatocellular Carcinoma) Biomarker Market Size Growth 2021-2026 (\$ millions)

Figure 41. France HCC (Hepatocellular Carcinoma) Biomarker Market Size Growth

2021-2026 (\$ millions)

Figure 42. UK HCC (Hepatocellular Carcinoma) Biomarker Market Size Growth

2021-2026 (\$ millions)

Figure 43. Italy HCC (Hepatocellular Carcinoma) Biomarker Market Size Growth

2021-2026 (\$ millions)

Figure 44. Russia HCC (Hepatocellular Carcinoma) Biomarker Market Size Growth

2021-2026 (\$ millions)

Figure 45. Middle East & Africa HCC (Hepatocellular Carcinoma) Biomarker Market Size Market Share by Region (2021-2026)

Figure 46. Middle East & Africa HCC (Hepatocellular Carcinoma) Biomarker Market Size Market Share by Type (2021-2026)

Figure 47. Middle East & Africa HCC (Hepatocellular Carcinoma) Biomarker Market Size Market Share by Application (2021-2026)

Figure 48. Egypt HCC (Hepatocellular Carcinoma) Biomarker Market Size Growth 2021-2026 (\$ millions)

Figure 49. South Africa HCC (Hepatocellular Carcinoma) Biomarker Market Size Growth 2021-2026 (\$ millions)

Figure 50. Israel HCC (Hepatocellular Carcinoma) Biomarker Market Size Growth 2021-2026 (\$ millions)

Figure 51. Turkey HCC (Hepatocellular Carcinoma) Biomarker Market Size Growth 2021-2026 (\$ millions)

Figure 52. GCC Countries HCC (Hepatocellular Carcinoma) Biomarker Market Size Growth 2021-2026 (\$ millions)

Figure 53. Americas HCC (Hepatocellular Carcinoma) Biomarker Market Size 2027-2032 (\$ millions)

Figure 54. APAC HCC (Hepatocellular Carcinoma) Biomarker Market Size 2027-2032 (\$ millions)

Figure 55. Europe HCC (Hepatocellular Carcinoma) Biomarker Market Size 2027-2032 (\$ millions)

Figure 56. Middle East & Africa HCC (Hepatocellular Carcinoma) Biomarker Market Size 2027-2032 (\$ millions)

Figure 57. United States HCC (Hepatocellular Carcinoma) Biomarker Market Size 2027-2032 (\$ millions)

Figure 58. Canada HCC (Hepatocellular Carcinoma) Biomarker Market Size 2027-2032 (\$ millions)

Figure 59. Mexico HCC (Hepatocellular Carcinoma) Biomarker Market Size 2027-2032 (\$ millions)

Figure 60. Brazil HCC (Hepatocellular Carcinoma) Biomarker Market Size 2027-2032 (\$ millions)

Figure 61. China HCC (Hepatocellular Carcinoma) Biomarker Market Size 2027-2032 (\$ millions)

Figure 62. Japan HCC (Hepatocellular Carcinoma) Biomarker Market Size 2027-2032 (\$ millions)

Figure 63. Korea HCC (Hepatocellular Carcinoma) Biomarker Market Size 2027-2032 (\$ millions)

Figure 64. Southeast Asia HCC (Hepatocellular Carcinoma) Biomarker Market Size 2027-2032 (\$ millions)

Figure 65. India HCC (Hepatocellular Carcinoma) Biomarker Market Size 2027-2032 (\$ millions)

Figure 66. Australia HCC (Hepatocellular Carcinoma) Biomarker Market Size 2027-2032 (\$ millions)

Figure 67. Germany HCC (Hepatocellular Carcinoma) Biomarker Market Size 2027-2032 (\$ millions)

Figure 68. France HCC (Hepatocellular Carcinoma) Biomarker Market Size 2027-2032 (\$ millions)

Figure 69. UK HCC (Hepatocellular Carcinoma) Biomarker Market Size 2027-2032 (\$ millions)

Figure 70. Italy HCC (Hepatocellular Carcinoma) Biomarker Market Size 2027-2032 (\$ millions)

Figure 71. Russia HCC (Hepatocellular Carcinoma) Biomarker Market Size 2027-2032 (\$ millions)

Figure 72. Egypt HCC (Hepatocellular Carcinoma) Biomarker Market Size 2027-2032 (\$ millions)

Figure 73. South Africa HCC (Hepatocellular Carcinoma) Biomarker Market Size 2027-2032 (\$ millions)

Figure 74. Israel HCC (Hepatocellular Carcinoma) Biomarker Market Size 2027-2032 (\$ millions)

Figure 75. Turkey HCC (Hepatocellular Carcinoma) Biomarker Market Size 2027-2032 (\$ millions)

Figure 76. Global HCC (Hepatocellular Carcinoma) Biomarker Market Size Market Share Forecast by Type (2027-2032)

Figure 77. Global HCC (Hepatocellular Carcinoma) Biomarker Market Size Market Share Forecast by Application (2027-2032)

Figure 78. GCC Countries HCC (Hepatocellular Carcinoma) Biomarker Market Size 2027-2032 (\$ millions)

I would like to order

Product name: Global HCC (Hepatocellular Carcinoma) Biomarker Market Growth (Status and Outlook) 2026-2032

Product link: <https://marketpublishers.com/r/G07CD6A4AD9BEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G07CD6A4AD9BEN.html>